gz402668
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2014 (NCT02282826)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- CAMPATH-1 antigenINHIBITOR
CD52 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- gz402668
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02977533 | Phase 1 | Dec 1, 2016 | Sanofi |
| NCT02282826 | Phase 1 | Oct 1, 2014 | Genzyme, Sanofi |
Showing 2 of 2 trials
Page 1 / 1